These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
291 related articles for article (PubMed ID: 24948044)
41. MGMT promoter methylation and field defect in sporadic colorectal cancer. Shen L; Kondo Y; Rosner GL; Xiao L; Hernandez NS; Vilaythong J; Houlihan PS; Krouse RS; Prasad AR; Einspahr JG; Buckmeier J; Alberts DS; Hamilton SR; Issa JP J Natl Cancer Inst; 2005 Sep; 97(18):1330-8. PubMed ID: 16174854 [TBL] [Abstract][Full Text] [Related]
42. Hypermethylation of the TPEF/HPP1 gene in primary and metastatic colorectal cancers. Ebert MP; Mooney SH; Tonnes-Priddy L; Lograsso J; Hoffmann J; Chen J; Röcken C; Schulz HU; Malfertheiner P; Lofton-Day C Neoplasia; 2005 Aug; 7(8):771-8. PubMed ID: 16207479 [TBL] [Abstract][Full Text] [Related]
43. Identification of MSX1 and DCLK1 as mRNA Biomarkers for Colorectal Cancer Detection Through DNA Methylation Information. Sun AJ; Gao HB; Liu G; Ge HF; Ke ZP; Li S J Cell Physiol; 2017 Jul; 232(7):1879-1884. PubMed ID: 27966796 [TBL] [Abstract][Full Text] [Related]
44. Quantitative assessment of AKAP12 promoter methylation in colorectal cancer using methylation-sensitive high resolution melting: Correlation with Duke's stage. Liu W; Guan M; Su B; Ye C; Li J; Zhang X; Liu C; Li M; Lin Y; Lu Y Cancer Biol Ther; 2010 Jun; 9(11):862-71. PubMed ID: 20364105 [TBL] [Abstract][Full Text] [Related]
45. XAF1 is frequently methylated in human esophageal cancer. Chen XY; He QY; Guo MZ World J Gastroenterol; 2012 Jun; 18(22):2844-9. PubMed ID: 22719195 [TBL] [Abstract][Full Text] [Related]
47. Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer. Galamb O; Kalmár A; Péterfia B; Csabai I; Bodor A; Ribli D; Krenács T; Patai ÁV; Wichmann B; Barták BK; Tóth K; Valcz G; Spisák S; Tulassay Z; Molnár B Epigenetics; 2016 Aug; 11(8):588-602. PubMed ID: 27245242 [TBL] [Abstract][Full Text] [Related]
48. Methylation profiles of multiple CpG island loci in extrahepatic cholangiocarcinoma versus those of intrahepatic cholangiocarcinomas. Kim BH; Cho NY; Choi M; Lee S; Jang JJ; Kang GH Arch Pathol Lab Med; 2007 Jun; 131(6):923-30. PubMed ID: 17550320 [TBL] [Abstract][Full Text] [Related]
49. NGX6 gene mediated by promoter methylation as a potential molecular marker in colorectal cancer. Liu M; Peng Y; Wang X; Guo Q; Shen S; Li G BMC Cancer; 2010 Apr; 10():160. PubMed ID: 20423473 [TBL] [Abstract][Full Text] [Related]
50. DNA methylation patterns as noninvasive biomarkers and targets of epigenetic therapies in colorectal cancer. Hashimoto Y; Zumwalt TJ; Goel A Epigenomics; 2016 May; 8(5):685-703. PubMed ID: 27102979 [TBL] [Abstract][Full Text] [Related]
51. Commonality and differences of methylation signatures in the plasma of patients with pancreatic cancer and colorectal cancer. Melson J; Li Y; Cassinotti E; Melnikov A; Boni L; Ai J; Greenspan M; Mobarhan S; Levenson V; Deng Y Int J Cancer; 2014 Jun; 134(11):2656-62. PubMed ID: 24288256 [TBL] [Abstract][Full Text] [Related]
52. Bile carcinoembryonic cell adhesion molecule 6 (CEAM6) as a biomarker of malignant biliary stenoses. Farina A; Dumonceau JM; Antinori P; Annessi-Ramseyer I; Frossard JL; Hochstrasser DF; Delhaye M; Lescuyer P Biochim Biophys Acta; 2014 May; 1844(5):1018-25. PubMed ID: 23806607 [TBL] [Abstract][Full Text] [Related]
53. Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients. Takane K; Midorikawa Y; Yagi K; Sakai A; Aburatani H; Takayama T; Kaneda A Cancer Med; 2014 Oct; 3(5):1235-45. PubMed ID: 24861485 [TBL] [Abstract][Full Text] [Related]
54. Circulating Methylated XAF1 DNA Indicates Poor Prognosis for Gastric Cancer. Ling ZQ; Lv P; Lu XX; Yu JL; Han J; Ying LS; Zhu X; Zhu WY; Fang XH; Wang S; Wu YC PLoS One; 2013; 8(6):e67195. PubMed ID: 23826230 [TBL] [Abstract][Full Text] [Related]
55. Aberrant promoter CpG islands methylation of tumor suppressor genes in cholangiocarcinoma. Uhm KO; Lee ES; Lee YM; Kim HS; Park YN; Park SH Oncol Res; 2008; 17(4):151-7. PubMed ID: 18773859 [TBL] [Abstract][Full Text] [Related]
56. Evaluating the utility of Nakasone ES; Zemla TJ; Yu M; Lin SY; Ou FS; Carter K; Innocenti F; Saltz L; Grady WM; Cohen SA Epigenetics; 2024 Dec; 19(1):2349980. PubMed ID: 38716804 [TBL] [Abstract][Full Text] [Related]
57. Global alterations of DNA methylation in cholangiocarcinoma target the Wnt signaling pathway. Goeppert B; Konermann C; Schmidt CR; Bogatyrova O; Geiselhart L; Ernst C; Gu L; Becker N; Zucknick M; Mehrabi A; Hafezi M; Klauschen F; Stenzinger A; Warth A; Breuhahn K; Renner M; Weichert W; Schirmacher P; Plass C; Weichenhan D Hepatology; 2014 Feb; 59(2):544-54. PubMed ID: 24002901 [TBL] [Abstract][Full Text] [Related]
58. Inactivation of helicase-like transcription factor by promoter hypermethylation in human gastric cancer. Leung WK; Yu J; Bai AH; Chan MW; Chan KK; To KF; Chan FK; Ng EK; Chung SC; Sung JJ Mol Carcinog; 2003 Jun; 37(2):91-7. PubMed ID: 12766908 [TBL] [Abstract][Full Text] [Related]
59. Genome-wide analysis of aberrant DNA methylation for identification of potential biomarkers in colorectal cancer patients. Fang WJ; Zheng Y; Wu LM; Ke QH; Shen H; Yuan Y; Zheng SS Asian Pac J Cancer Prev; 2012; 13(5):1917-21. PubMed ID: 22901147 [TBL] [Abstract][Full Text] [Related]
60. Epigenetic biomarkers of promoter DNA methylation in the new era of cancer treatment. Yamashita K; Hosoda K; Nishizawa N; Katoh H; Watanabe M Cancer Sci; 2018 Dec; 109(12):3695-3706. PubMed ID: 30264476 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]